Jeffrey J. Kooijman

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors

Neil T. Conlon, Jeffrey J. Kooijman, Suzanne J.C. van Gerwen et al. · British Journal of Cancer · 2021 · 68 citations · Full text

Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines

Gisele Nishiguchi, Lauren G. Mascibroda, Sarah M. Young et al. · Nature Communications · 2024 · 37 citations · Full text

Tumor Biology, Protein Function, Broad Range +15

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017

Joost C.M. Uitdehaag, Jeffrey J. Kooijman, Jeroen A.D.M. de Roos et al. · Molecular Cancer Therapeutics · 2018 · 27 citations

Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020

Jeffrey J. Kooijman, Wilhelmina E. van Riel, Jelle Dylus et al. · Frontiers in Oncology · 2022 · 20 citations · Full text

Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors

Joost C.M. Uitdehaag, Jeroen A.D.M. de Roos, Martine B.W. Prinsen et al. · Molecular Cancer Therapeutics · 2016 · 18 citations